The Rotation of Disinfectants Principle: True or False? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Rotation of Disinfectants Principle: True or False?
The author defines sanitizers, disinfectants, and antibiotics, and examines the question of whether the rotation of disinfectants is scientifically warranted.


Pharmaceutical Technology
Volume 33, Issue 2, pp. 58-71

20. A. Quentmeier and C.G. Friedrich, "Transfer and Expression of Degradative and Antibiotic Resistance Plasmids in Acidophilic Bacteria," Appl. Environ. Microbiol. 60 (3), 973–978 (1994).

21. L.M. McMurray, M. Oethinger, and S.B. Levy, "Triclosan Targets Lipid Synthesis," Nature 394, 531–532 (1998).

22. P.J. Baker et al., "Molecular Basis of Triclosan Activity," Nature 398, 383–384 (1999).

23. D.J. Payne, et al. "Defining and Combating the Mechanisms of Triclosan Resistance in Clinical Isolates of Staphylococcus aureus, " Antimicrob. Agents Chemother. 46 (11), 3343–3347 (2002).

24. M. Braoudaki and A.C. Hilton, "Adaptive Resistance to Biocides in Salmonella enterica and Escherichia coli O157 and Cross-Resistance to Antimicrobial Agents," J. Clin. Microbiol. 42 (1), 73–78 (2004).

25. L.M. McMurry, M. Oethinger, and S.B. Levy, "Overexpression of marA, soxS, or acrAB Produces Resistance to Triclosan in Laboratory and Clinical Strains of Escherichia coli, " FEMS Microbiol. Lett. 166 (2), 305–309 (1998).

26. A.E. Aiello, et al., "Relationship between Triclosan and Susceptibilities of Bacteria Isolated from Hands in the Community," Antimicrob. Agents Chemother. 48 (8), 2973–2979 (2004).

27. Colgate-Palmolive Co., "Antibacterial Compositions," GB 1090020, Nov. 8, 1967.

28. S.B. Levy, "Antibacterial Household Products: Cause for Concern," Emerg. Infect. Dis. 7, 512–515 (2001).

29. T.T. Hoang and H.P. Schweizer, "Characterization of the Pseudomonas aeruginosa Enoyl-Acyl Carrier Protein Reductase: A Target for Triclosan and Its Role in Acylated Homoserine Lactone Synthesis," J. Bacteriol. 181 (17), 5489–5497 (1999).

30. H.P. Schweizer, "Intrinsic Resistance to Inhibitors of Fatty Acid Biosynthesis in Pseudomonas aeruginosa Is Due to Efflux: Application of a Novel Technique for Generation of Unmarked Chromosomal Mutations for the Study of Efflux Systems," Antimicrob. Agents Chemother. 42 (2), 394–398 (1998).

31. P. Plesiat et al., "Use of Steroids to Monitor Alterations in the Outer Membrane of Pseudomonas aeruginosa, " J. Bacteriol. 179 (22), 7004–7010 (1997).

32. C.K. Hope and M. Wilson, "Analysis of the Effects of Chlorhexidine on Oral Biofilm Vitality and Structure Based on Viability Profiling and an Indicator of Membrane Integrity," Antimicrob. Agents Chemother. 48 (5), 1461–1468 (2004).

33. A.D. Russell and M.J. Day, "Antibacterial Activity of Chlorhexidine," J. Hosp. Infect. 25, 229–238 (1993).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here